EUCTR2014-005493-11-FR进行中（未招募）1 期
Intrathecal Rituximab in Progressive Multiple Sclerosis - EFFRITE
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Age =45 years, male or female ;
- •Secondary or primary progressive MS, in progressive phase since >2 years ;
- •EDSS =6.0 ;
- •Absence of alternative therapy.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 12
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Relapsing-remitting phase of MS;
- •Contraindication to MRI, lumbar puncture, Trendelenburg position ;
- •Active infection or immunosuppressive state or treatment (actual or less than 6 months);
- •Severe heart failure or uncontrolled severe heart disease.
- •Earlier treatment with rituximab;
- •Dementia or severe psychiatric disorder.
研究者
相似试验
终止
1 期
Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)Multiple SclerosisNCT01212094National Institute of Neurological Disorders and Stroke (NINDS)44
尚未招募
不适用
INFLUENCE OF B CELL DEPLETION BY MONOCLONAL ANTI-CD20 ANTIBODIES IN SYSTEMIC SCLERODERMATo evaluate the safety and efficacy of anti-CD20 therapy with respect to:-Clinical and laboratory adverse events, as measured every three months.-Survival and prevention of major organ failure (referred to as ¡¥event-free survival¡¦ which is considered the primary endpoint).-Impact on skin thickening, visceral involvement, functional status, and quality of lifeNL-OMON24091ROCHE20
进行中（未招募）
1 期
Rituximab as second line treatment for ITP:A Multicentre, Randomized, Double blind, Placebo-controlled, Phase III study.The RITP study” - RITP studyImmune thrombocytopenic purpura (ITP)MedDRA version: 9.1Level: LLTClassification code 10021245Term: Idiopathic thrombocytopenic purpuraEUCTR2005-005918-20-FRRikshospitalet110
进行中（未招募）
1 期
Rituximab as second line treatment for ITP. A Multicentre, Randomized, Double blind, Placebo-controlled, Phase III study. - RITP studyEUCTR2005-005918-20-SESykehuset Østfold, Fredrikstad20
进行中（未招募）
1 期
The efficacy of treatment of patients with multiple sclerosis, a chronic, inflammatory, autoimmune, disease that leads to neurologic deficits and aggravates with flairs, with low doses of rituximab, an antibody directed against the CD20 epitope on B Lymphocytes, specific cells of the immune system contributing to the progression of the disease - a pilot trialRelapse Remitting Multiple SclerosisMedDRA version: 20.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2017-000426-35-ATMedical University of Vienna - Department of Neurology70